[PROVISIONAL] Large miRNA survival analysis reveals a prognostic four-biomarker signature for triple negative breast cancer
AUTOR(ES)
Andrade, Fernando
FONTE
Genet. Mol. Biol.
DATA DE PUBLICAÇÃO
05/09/2019
RESUMO
Abstract Triple negative breast cancer (TNBC) is currently the only major breast tumor subtype without effective targeted therapy and, as a consequence, usually presents a poor outcome. Due to its more aggressive phenotype, there is an urgent clinical need to identify novel biomarkers that discriminate individuals with poor prognosis. Our hypothesis is that miRNAs can be used to this end because they are involved in the initiation and progression of tumors by altering the expression of their target genes. To identify a prognostic biomarker in TNBC, we analyzed the miRNA expression of a cohort composed of 185 patients diagnosed with TNBC using penalized Cox regression models. We identified a four-biomarker signature based on miR-221, miR-1305, miR-4708, and RMDN2 expression levels that allowed for the subdivision of TNBC into high- or low-risk groups (Hazard Ratio - HR=0.32; 95% Confidence Interval - CI = 0.11–0.91; p=0.03) and are also statistically associated with survival outcome in subgroups of postmenopausal status (HR=0.19; 95%CI = 0.04–0.90; p=0.016), node negative status (HR=0.12; 95%CI = 0.01–1.04; p=0.026), and tumors larger than 2cm (HR=0.21; 95%CI = 0.05–0.81; p=0.021). This four-biomarker signature was significantly associated with TNBC as an independent prognostic factor for survival.
Documentos Relacionados
- Expression analysis of miRNA and target mRNAs in esophageal cancer
- MicroRNA 100: a context dependent miRNA in prostate cancer
- Repertoire and evolution of miRNA genes in four divergent nematode species
- The action of ARGONAUTE1 in the miRNA pathway and its regulation by the miRNA pathway are crucial for plant development
- Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer